Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

May 31, 2002

Study Completion Date

May 31, 2002

Conditions
Lymphoma
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

rituximab

Trial Locations (1)

14642

University of Rochester Cancer Center, Rochester

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Rochester

OTHER

NCT00003356 - Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | Biotech Hunter | Biotech Hunter